Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
18
17
15
N/A
0
13
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+10 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mojca Jongen-Lavrencic, MD
Erasmus Medical Center
Shared therapeutic areas:
Worked with same sponsors:
David A Rizzieri, MD
Duke University
Shared therapeutic areas:
Worked with same sponsors:
Raoul Tibes, MD
Mayo Clinic Scottsdale-Phoenix
Shared therapeutic areas:
Worked with same sponsors:
Jesus Berdeja, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Worked with same sponsors:
Hartmut Döhner, MD
Universitätsklinikum Ulm
Shared therapeutic areas:
Worked with same sponsors:
Martin S. Tallman, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jessica Altman, MD
Northwestern University
Shared therapeutic areas:
Worked with same sponsors:
Boon Cher Goh, M.D.
National University Hospital, Singapore
Shared therapeutic areas:
Worked with same sponsors:
Charles Chuah, M.D.
Singapore General Hospital
Shared therapeutic areas:
Worked with same sponsors:
George Wilding, M.D.
University of Wisconsin, Madison
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase II 5-Azacytidine Plus VPA Plus ATRA
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
All 18 trials loaded